Type 2 Diabetes

With the newest indication, the GLP-1 agonist is now available in 3 different doses for diabetic adults.

Severe and level 2 hypoglycemia has continued to occur in individuals with type 1 diabetes and high hypoglycemia risks despite technological advancements.

Higher BMI in overweight category at midlife was associated with a greater burden of overall and CVD morbidity, as well as higher health care costs in older adulthood.

A user fee goal date of August 17, 2022 has been assigned to teplizumab.

Alcohol use was additionally associated with worse fibrosis, but no interaction was noted between the two risk factors.

The phase 3 trial was stopped following a formal interim assessment that met pre specified criteria for positive efficacy in patients with chronic kidney disease.

Data show LNCSBs as a substitute for sugar-sweetened beverages were associated with reduced body weight, BMI, percentage of body fat, and intrahepatocellular lipid.

More studies need to be done examining the associations of increased weight and outcomes among patients with cystic fibrosis.

A look into the uptake of semaglutide, what the agent represents, and what is coming further in obesity management.

Pregnant women who experienced only spontaneous abortion or both spontaneous and induced abortion were at higher risk of developing gestational diabetes.

Lifestyle interventions had no statistically significant difference in reducing worsening glycemic status compared to usual care in women with gestational diabetes.

The use of GLP-1 receptor agonists was associated with lower all-cause mortality and lower sepsis- and infection-related mortality compared to DPP-4 inhibitors.

Dr. Serge Jabbour led the panel in discussing emerging treatments for type 2 diabetes.

Dr. Granger discusses the current underuse of these agents and the steps cardiologists need to take to increase prescription rates and uptake for patients.

Dr. Pagidipati highlights her own approach to weight management, from lifestyle changes, diet, and medication to metabolic procedures.

From a couple of novel heart failure treatments to a promising dual receptor agonist, here's a rundown of expected pipeline news this year in heart disease.

General progress has been made in decreasing diabetes mortality at ages younger than 25 years, but challenges remain in low and low-middle SDI countries.

Pupillary dilation and manual eyelid lifting were shown to substantially increase visible retinal area and PLL-HMA detection using fully automated algorithms.

The treatment is indicated to reduce the risk of cardiovascular death and hospitalization in a wider range of adult patients with heart failure.

Obesity was added to the list of risk factors for influenza in 2009.

The estimated mean change in body weight from baseline to week 68 was -13.2% in the semaglutide 2.4 mg group versus -2.1% in the placebo group.

Higher variability of adiposity indices was associated with significantly increased risk of CVD outcomes in standard of care, but not in the intensive lifestyle intervention group.

Data show fewer than 1 in 20 patients with diabetes and ASCVD were prescribed a high-intensity statin, either an ACEI or ARB, and either an SGLT2I and/or a GLP-1RA.

The percentage of time with glucose level in the target range was 8.7 percentage points higher during the closed-loop period compared to control.

New guidelines recommend healthcare providers develop and implement an individualized nutrition care plan for individuals with diabetes with or at risk of a DFU.

A higher percentages of patients treated with tirzepatide had HbA1c less than 7% versus those treated with placebo (85%-90% versus 34%).

Cardiovascular disease is the leading cause of death for women.

Rates of aspirin use for preeclampsia prophylaxis were observed in a minority of women with risk factors including pre-pregnancy diabetes, obesity, or chronic hypertension.

There was not an association between sleep duration and metabolic diseases found in men.

An increase of 57% in new-onset type 1 diabetes admissions was observed from March 2020 - 2021.